Treatment patterns and survival in metastatic breast cancer patients by tumor characteristics

References

• American Cancer Society: Cancer Facts and Figures 2013–2014, Atlanta. American Cancer Society, 2014. Available at http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042725.pdf [Last accessed 16 May 2014]
   Google Scholar
• Stopeck A, Chalasani P, Thompson P, et al. Breast Cancer. Medscape Reference, 2014. Available at http://emedicine.medscape.com/article/1947145-overview#showall [Last Accessed 15 January 2014]
   Google Scholar
• Jones SE. Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 2008;8:224-33
   PubMed Web of Science ®Google Scholar
• Treatment Options for HER2-Positive Breast Cancer Expand and Evolve. National Cancer Institute Cancer Bulletin 2012:9(20). Available at: www.cancer.gov/ncicancerbulletin/101612/page2 [Last accessed 16 September 2013]
   Google Scholar
• Incorvati JA, Shah S, Mu Y, Lu J. Targeted therapy for HER2 positive breast cancer. J Hematol Oncol 2013;6:38
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines), Breast Cancer (version 1.2014). Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf [Last accessed 12 February 2014]
   Google Scholar
• Partridge AH, Gelber S, Piccart-Gebhart MJ, et al. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 2013;31:2692-8
   PubMed Web of Science ®Google Scholar
• Kaufman PA, Brufsky AM, Mayer M, et al. Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat 2012;135:875-83
   PubMed Web of Science ®Google Scholar
• Sharma PP, Sail K, Delea T, Patt D. Treatment patterns in HER2/HR postmenopausal women with metastatic breast cancer initiating first-line treatment in a community oncology setting in the US. Community Oncol 2013;10:74-81
   Google Scholar
• Tripathy D, Kaufman PA, Brufsky AM, et al. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist 2013;18:501-10
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Ensor J, et al. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 2010;21:2169-74
   PubMed Web of Science ®Google Scholar
• Rossi V, Nolè F, Redana S, et al. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. Breast 2014;23:44-9
   PubMed Web of Science ®Google Scholar
• Yardley DA, Kaufman PA, Brufsky A, et al. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2014 Jun;145(3):725-34
   Google Scholar
• Hines RB, Chatla C, Harvey L. Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer. J Clin Oncol 2009;27:4339-45
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-9
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010;28:92-8
   PubMed Web of Science ®Google Scholar
• Thientosapol ES, Tran TT, Della-Fiorentina SA, et al. Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials. Intern Med J 2013;43:883-8
   PubMed Web of Science ®Google Scholar
• Largillier R, Ferrero JM, Doyen J, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 2008;19:2012-19
   PubMed Web of Science ®Google Scholar
• Vaz-Luis I, Ottesen RA, Hughes ME, et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res 2012;14:R129
   PubMed Web of Science ®Google Scholar
• Liang SY, Phillips KA, Wang G, et al. Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Med Care 2011;49:e1-8
   PubMed Web of Science ®Google Scholar